[8-K] STRATA Skin Sciences, Inc. Reports Material Event

Rhea-AI Filing Summary

Strata Skin Sciences reported it remains out of compliance with Nasdaq’s minimum $2,500,000 stockholders’ equity requirement. Nasdaq accepted the company’s plan and granted an extension until February 16, 2026 to regain compliance.

The company is evaluating actions discussed with Nasdaq. If compliance is not regained by the deadline, the common stock could become subject to delisting, though the company would be permitted to request a hearing, which would stay any suspension or delisting action during the process.

Insights

Listing & Capital Markets Analyst

Nasdaq accepted a compliance plan; delisting risk remains if not met.

Strata Skin Sciences received confirmation that Nasdaq accepted its plan to address the minimum $2,500,000 stockholders’ equity requirement. The company now has until February 16, 2026 to demonstrate compliance.

The extension avoids immediate action but does not resolve the deficiency. If compliance is not achieved by the deadline or other listing rules are breached, the stock could face delisting, with an appeal process available that would stay any suspension during a hearing.

Key items hinge on management’s steps to rebuild equity as outlined to Nasdaq. Subsequent disclosures may detail any capital measures or earnings-driven improvements the company uses to meet the threshold.

false 0001051514 0001051514 2025-10-13 2025-10-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 13, 2025

STRATA SKIN SCIENCES, INC.

(Exact name of registrant as specified in its Charter)

Delaware		000-51481		13-3986004
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

5 Walnut Grove Drive, Suite 140

Horsham, Pennsylvania 19044

(Address of principal executive offices) (Zip Code)

215-619-3200

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0,001 par value per share		SSKN		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed on August 22, 2025, Strata Skin Sciences, Inc. (the “Company”) received a deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”). On September 19, 2025, the Company submitted a plan to Nasdaq to regain compliance with the Stockholders’ Equity Requirement (the “Plan”).

In response to the Company’s Plan, on October 13, 2025, Nasdaq provided the Company notice that Nasdaq has accepted the Plan and granted the Company an extension until February 16, 2026, to regain compliance with the Stockholders’ Equity Requirement.

The Company is currently evaluating various courses of action discussed with Nasdaq to regain compliance. There can be no assurance that the Company will be able to regain compliance. If the Company does not regain compliance by February 16, 2026, or if the Company fails to satisfy another Nasdaq requirement for continued listing, Nasdaq could provide notice that the Company’s common stock will become subject to delisting. In such event, Nasdaq rules permit the Company to appeal any delist determination. The hearing request would stay any suspension or delisting action pending the conclusion of the hearing process and the expiration of any additional extension period granted by the panel following the hearing.

Forward-Looking Statements

Certain statements contained in this Current Report on Form 8-K are not historical facts and are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. This information includes, without limitation, statements concerning the Company’s intention or ability to regain compliance with the applicable Nasdaq listing requirements, the Company’s intention to appeal the Nasdaq staff’s determination, the Company’s expectation that a request for a Panel hearing will stay the suspension of the Company’s securities pending the Panel’s decision, the timing and nature of any hearing before the Panel, the outcome of the Panel’s review of any Company appeal of the Nasdaq staff’s determination, and any courses of action to regain compliance with the applicable Nasdaq listing requirements. Words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “seeks,” and similar expressions are intended to identify forward-looking statements. The Company may not actually achieve the plans and objectives disclosed in the forward-looking statements, and you should not place undue reliance on the Company’s forward-looking statements. Any forward-looking statements are based on management’s current views and assumptions and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. These and other risks are described more fully in the Company’s filings with the Securities and Exchange Commission (SEC), including the “Risk Factors” section of its annual report on Form 10-K for the fiscal year ended December 31, 2024, and any risks that may be contained in any subsequent filings that the Company makes with the SEC. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		STRATA SKIN SCIENCES, INC.
Dated: October 14, 2025		By:	/s/ John Gillings
			John Gillings
			Chief Accounting Officer

2

FAQ

What did SSKN announce regarding its Nasdaq listing?

Nasdaq accepted the company’s plan to regain compliance and granted an extension until February 16, 2026.

What is the minimum equity requirement SSKN must meet?

Nasdaq Listing Rule 5550(b)(1) requires $2,500,000 stockholders’ equity.

What happens if SSKN does not regain compliance by February 16, 2026?

Its common stock could become subject to delisting, with the right to request a hearing that stays any suspension during the process.

What steps is SSKN taking to regain compliance?

The company is evaluating various courses of action discussed with Nasdaq as part of its accepted plan.

Does SSKN have the right to appeal a delisting notice?

Yes. A hearing request would stay any suspension or delisting action pending the panel’s decision and any extension granted.